Patents by Inventor Michel Thiry
Michel Thiry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11883531Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.Type: GrantFiled: July 13, 2020Date of Patent: January 30, 2024Assignee: ILTOO PHARMAInventors: Jérémie Mariau, Michel Thiry
-
Publication number: 20210128465Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.Type: ApplicationFiled: July 13, 2020Publication date: May 6, 2021Applicant: ILTOO PHARMAInventors: Jérémie MARIAU, Michel THIRY
-
Patent number: 10722460Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.Type: GrantFiled: October 20, 2016Date of Patent: July 28, 2020Assignee: ILTOO PharmaInventors: Jérémie Mariau, Michel Thiry
-
Publication number: 20180303754Abstract: The invention relates to a liquid pharmaceutical composition of I1-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.Type: ApplicationFiled: October 20, 2016Publication date: October 25, 2018Applicant: ILTOO PHARMAInventors: Jérémie MARIAU, Michel THIRY
-
Patent number: 9796767Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: January 19, 2016Date of Patent: October 24, 2017Assignee: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Patent number: 9790259Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: January 19, 2016Date of Patent: October 17, 2017Assignee: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Patent number: 9409991Abstract: A pharmaceutical composition for prevention or treatment of viral infections including a formulation of full antibodies or fragments of antibodies specific to at least one of the following peptide sequences of toll-like receptor type 3: FYWNVSVHRVLGFKE (Seq ID NO:1), EYAAYIIHAYKD (Seq ID NO: 2), or to peptide sequence of interferon gamma receptor beta chain: LIKYWFHTPPSIPLQIEEYL (Seq ID NO: 3), or to peptide sequence of interferon gamma receptor alpha chain: SIILPKSLISW (Seq ID NO: 4).Type: GrantFiled: June 26, 2009Date of Patent: August 9, 2016Assignee: THERANOR SPRLInventors: Michel Thiry, Andrey Martyushev-Poklad
-
Patent number: 9409960Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: April 7, 2008Date of Patent: August 9, 2016Assignee: Symbiotec Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20160130313Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: PETER GROSS, HANS JORNVALL, GRAZYNA FORMICKA-ZEPPEZAUER, MICHAEL ZEPPEZAUER, MICHEL THIRY
-
Publication number: 20160130312Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: January 19, 2016Publication date: May 12, 2016Applicant: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20110177081Abstract: A pharmaceutical composition for prevention or treatment of viral infections including a formulation of full antibodies or fragments of antibodies specific to at least one of the following peptide sequences of toll-like receptor type 3: FYWNVSVHRVLGFKE (Seq ID NO:1), EYAAYIIHAYKD (Seq ID NO: 2), or to peptide sequence of interferon gamma receptor beta chain: LIKYWFHTPPSIPLQIEEYL (Seq ID NO: 3), or to peptide sequence of interferon gamma receptor alpha chain: SIILPKSLISW (Seq ID NO: 4).Type: ApplicationFiled: June 26, 2009Publication date: July 21, 2011Applicant: Theranor SPRLInventors: Michel Thiry, Andrey Martyushev-Poklad
-
Publication number: 20110034370Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: ApplicationFiled: April 7, 2008Publication date: February 10, 2011Inventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Publication number: 20100330174Abstract: The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO? with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that the second compound is different from the first compound and in an amount by weight at least three times the amount of first compound.Type: ApplicationFiled: August 25, 2010Publication date: December 30, 2010Applicant: BIO ETHIC SPRL.Inventors: Jallal Messadek, Rachid Ennamany, Michel Thiry
-
Patent number: 7754223Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention further provides recombinant Yersinia ruckeri cells to be used to construct vaccines against SRS. The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.Type: GrantFiled: October 1, 2004Date of Patent: July 13, 2010Assignee: Eurogentec SAInventors: Michel Thiry, Ingrid Dheur
-
Publication number: 20070207165Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention further provides recombinant Yersinia ruckeri cells to be used to construct vaccines against SRS. The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.Type: ApplicationFiled: October 1, 2004Publication date: September 6, 2007Inventors: Michel Thiry, Ingrid Dheur
-
Patent number: 5587190Abstract: The present invention relates to a dietary composition intended to be absorbed before, during or after an activity, which comprises carbohydrates and lipids, said lipids constituting 10 to 55% of the calorie content of the composition.Type: GrantFiled: March 21, 1995Date of Patent: December 24, 1996Assignee: Pernod RicardInventors: Yannick Guezennec, Joseph Koziet, Michel Thiry
-
Patent number: D1021758Type: GrantFiled: November 11, 2022Date of Patent: April 9, 2024Assignee: The Goodyear Tire & Rubber CompanyInventors: Pierre-Yves Andre Ghislain Chauveheid, Stephane Jose Geelen, Stephane Laurent Claude Bokken, Thierry Maurice Luc, Francois-Michel Thiry